drugset / Trial / NCT00312013

Effects Of Nadroparin In Patients With Lung, Pancreas Or Prostate Cancer

NCT00312013

Phase 3 Completed 503 enrolled GlaxoSmithKline
RandomizedParallel-groupOpen-labelTreatment

Summary

This study will evaluate the effects of nadroparin on survival and disease progression in patients with hormone-refractory prostate cancer (HRPC), locally advanced pancreatic cancer or non-small-cell lung carcinoma (NSCLC).

Timeline

Start
2006-05
Primary completion
2009-07
Completion
2009-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Nadroparin Calcium Other / unclassified Subcutaneous